CORRESP Filing
Moleculin Biotech, Inc.
Date: June 17, 2025 · CIK: 0001659617 · Accession: 0001437749-25-020612
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287727
Letter
mbrx20250617c_corresp.htm
Roth Capital Partners, LLC
888 San Clemente Drive
Newport Beach, CA 92660
June 17, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Washington, DC 20549
Re:
Moleculin Biotech, Inc.
Registration Statement on Form S-1 (Registration No. 333-287727)
Concurrence in Acceleration Request
Ladies and Gentlemen:
Roth Capital Partners, LLC (“ Roth ”), as placement agent for the referenced offering, hereby concurs in the request by Moleculin Biotech, Inc. that the effective date of the above-referenced registration statement be accelerated to 9:00 a.m. (Eastern Time), or as soon as practicable thereafter, on Wednesday, June 18, 2025, pursuant to Rule 461 under the Securities Act. Roth affirms that it is aware of its obligations under the Securities Act in connection with this offering.
[ Signature Page Follows ]
Very truly yours,
ROTH CAPITAL PARTNERS, LLC
Show Raw Text
CORRESP 1 filename1.htm mbrx20250617c_corresp.htm Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, CA 92660 June 17, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, DC 20549 Re: Moleculin Biotech, Inc. Registration Statement on Form S-1 (Registration No. 333-287727) Concurrence in Acceleration Request Ladies and Gentlemen: Roth Capital Partners, LLC (“ Roth ”), as placement agent for the referenced offering, hereby concurs in the request by Moleculin Biotech, Inc. that the effective date of the above-referenced registration statement be accelerated to 9:00 a.m. (Eastern Time), or as soon as practicable thereafter, on Wednesday, June 18, 2025, pursuant to Rule 461 under the Securities Act. Roth affirms that it is aware of its obligations under the Securities Act in connection with this offering. [ Signature Page Follows ] Very truly yours, ROTH CAPITAL PARTNERS, LLC By: /s/ Louis J. Ellis Name: Louis J. Ellis Title: Managing Director, Equity Capital Markets